Since the first examples of CBRN agents being used in warfare, developments in treatment and prevention have been struggling to keep up. Options to mitigate the harmful effects of CBRN agents on the civilian population have been relatively limited until recent years.
With President Donald Trump’s withdrawal from the Joint Comprehensive Plan of Action, more commonly referred to as the Iran Deal, and summit with North Korean leader, Kim Jong Un, in Singapore, the US leader has shown a significant lack of consistency on the issue of nuclear proliferation. The president’s apparent preference for “going it alone” has…